According to Prostate Cancer UK, prostate cancer is the most common cancer in men: 1 in 8 men will get it and if you’re over 50, or you’re Black, or you have a family history of the disease, then your ...

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical ...

Study reveals geographic differences in the use of innovative technological approaches to diagnose and treat prostate cancer. The study looked at the effect of regional hospital competition and ...

One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

Read more in the PNW Health series. Prostate cancer is the second-most common cancer among men in the U.S., affecting 13 out of every 100 American men over the course of their lifetime. About two to ...

Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial ...

(MENAFN- GlobeNewsWire - Nasdaq) STEAP1 and STEAP2 present significant opportunities as therapeutic targets in prostate cancer treatment due to their high expression in tumors and limited expression ...

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...

Given the low mortality from slow-growing, localized prostate cancers and the side effects of many treatments, deciding whether to opt for monitoring or treatment can be excruciatingly difficult.